Vertex Pharmaceuticals Incorporated
As of Oct 22, 2026, Vertex Pharmaceuticals is in Stage 2, the uptrend phase, now in week 17 (since Jun 29, 2026). It closed at $535.17, 4.1% below its 52-week high and above its 200-day average, which is rising.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is VRTX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VRTX among Biotechnology126th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …126 | VRTX | Stage 2 · wk 17 | 73 | +3.6% |
Vertex Pharmaceuticals: quick answers
What stage is Vertex Pharmaceuticals in?
As of Oct 22, 2026, Vertex Pharmaceuticals (VRTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 29, 2026 and is in week 17. What the four stages mean
Is Vertex Pharmaceuticals in an uptrend?
Yes. Vertex Pharmaceuticals is in a Stage 2 uptrend. It trades 12.2% above its 200-day average, which is rising.
How far is Vertex Pharmaceuticals from its 52-week high?
Vertex Pharmaceuticals closed at $535.17 on Oct 22, 2026, 4.1% below its 52-week high of $557.96. Its 52-week low is $409.47.
How has Vertex Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Vertex Pharmaceuticals is up 25.5% over the past year and up 18.4% so far in 2026.
Which sector and industry is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.